Possible use of the drugsecuritel/valsartan (of aperio)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In this article, a literature review of domestic and foreign sources on the use of the combined drug sacubitril/valsartan (uperio) was conducted, which showed that it can be used in patients suffering from CHF with a reduced ejection fraction of <40% and >45%. In the above sources, it is proved that the use of the drug securitel/vaIsartan (of aperio) leads to improved functional class of CHF and reduced requirements for diuretic therapy and improve tolerance to physical activity and quality of life of patients and reducing mortality from cardiovascular disease and admission to a hospital about CHF. The positive aspects of the use of the combination of sacubitril/valsartan in comorbid patients with chronic kidney disease and heart failure, even with a reduced ejection fraction in end-stage kidney disease, are shown. Sacubitril/valsartan may be recommended for use in patients with CHF and diabetes mellitus, taking into account the dose adjustment of hypoglycemic therapy. The data of studies on the use of sacubitril/valsartanau in patients with hypertension are presented, which confirm a good antihypertensive effect compared to other drugs for the treatment of elderly people suffering from systolic arterial hypertension and/or increased blood pressure mainly at night, resistant to drug therapy. Positive research results, as well as a good safety profile, indicate the possibility of using the drug sacubitril/valsartan in clinical practice.

Full Text

Restricted Access

About the authors

E. V Okladnikova

Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky

Ph.D (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Counseling with a Postgraduate Course

I. V Gackich

Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky

Ph.D (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Counseling with a Postgraduate Course

T. V Potupchik

Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky

Email: potupchik_tatyana@mail.ru
Ph.D (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Counseling with a Postgraduate Course

References

  1. Хроническая сердечная недостаточность. Клинические рекомендации. 2020.
  2. CumuuKoea М.Ю., Юрченко А.В., Лясникоеа Е.А., Трукшина М.А., Либис Р.А., Кондратенко В.Ю., Дупляков Д.В., Хохлунов С.М., Е. В. Шляхто Е.В. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология, 2015;55(10): 13-21. doi: 10.18565/саrdio.2015.10.5-13
  3. Фомин И.В. Артериальная гипертония в Российской Федерации - последние 10 лет. Что дальше? Сердце: журнал для практикующих врачей. 2007; 6(3): 1-6.
  4. Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Агеев Ф. Т. и др. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа. 2010.
  5. Cleland J.G., Swedberg К., Follath F. Komajda М., Cohen-Solal A., Aguilar J.C., Dietz R., Gavazzi A., Hobbs R., Korewicki J., Madeira H.C., Moiseyev V.S., Preda I., van Gilst W.H, Widimsky J., Freemantle N, Eastaugh J. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24 (5):442-463 .doi: 10.1016/sO 195-668x(02)00823-0.
  6. Агеев Ф.Т., Даниелян M.O., Мареев В.Ю., Беленков Ю.Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Сердечная недостаточность 2004; 5(1 ):4-7.
  7. Даниелян М.О. Прогноз и лечение хронической сердечной недостаточности (данные 20-и летнего наблюдения): Автореф. дисс...канд. мед. наук. М. 2001.
  8. Фомин И.В.,Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Бадин Ю.В., Галявич А.С., Даниелян М.О., Камалов Г.М., Колбин А.А., Кечеджиева С.Г., Макарова В.Г., Макарова Н.В., Маленкова В.Ю., Сайфутдинов Р.И., Тарловская Е.И., Хохлов Р.А., Щербинина Е.В., Якушин С.С. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА -ХСН. Сердечная недостаточность. 2006; 7(1): 112-115.
  9. Бадин Ю.В., Фомин И.В. Выживаемость больных ХСН в когортой выборке Нижегородской области (данные 1998-2002 годов.). Всероссийская конференция ОССН: Сердечная недостаточность. 2005. М. 2005.
  10. Якушин С.С., Смирнова Е.А., Лиферов Р.А. Выживаемость больных хронической сердечной недостаточностью (данные когортного исследования репрезентативной выборки населения Рязанской области). Сердечная недостаточность. 2011; 12(4):218-221.
  11. Фомин И.В. Хроническая сердечная недостаточность в Российской федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7-13.https://doi.org/10.15829/1560-4071-2016-8-7-13.
  12. Lam C.S.P., Solomon S.D. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur. J. Heart Fail. 2014; 16:1049-1055. D01:10.1002/ejhf.l59.
  13. Терещенко C.H., Жиров И.В., Нарусов О.Ю., Мареев Ю.В., Затейщиков Д.А., Осмоловская Ю.Ф., Овчинников А.Г., Самко А.Н., Насонова С.Н., Стукалова О.В., Саидова М.А., Скворцов А.А., Шария М.А., Явелов И.С. Диагностика и лечение хронической и острой сердечной недостаточности. Кардиологический вестник. 2016; 2:3-33.
  14. Chen J., Normand S.L., Wang Y., Krumholz H.M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011; 306(15):1669-1678.doi: 10.1001/jama.2011.1474.
  15. Dunlay S.M., Redfield M.M., Weston S.A., Themeau T.M., Long K.H., Shah N.D., Roger V.L. Hospitalizations after heart failure diagnosis a community perspective. J. Am.Coll. Cardiol. 2009; 54 (18): 1695-1702.
  16. Me Murray J. Clinical practice. Systolic heart failure. N. Engl. J. Med. 2010; 362(3):228-238. doi: 10.1056/NEJMcp0909392.
  17. Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume М., Sohanpal S., Sanders S., Hobbs F.D.R. Systematic review and individual patient data metaanalysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol. Assess. 2009; 13:1-207.
  18. Dimopoulos K., Saukhe T.V., Coats A., Mayet J., Piepoli М., Francis D.P. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int. J.Cardiol. 2004; 93(2-3): 105-111.
  19. Maggioni A.P., Anand I., Gottlieb S.O., et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme inhibitors. J. Am. Coll. Cardiol. 2002; 40(8): 1414-1421.
  20. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.-L., Kober L.,Maggioni A.P., Solomon S.D., Swedberg K., Van de Wetf F., White H., Leimberger J.D., Henis М., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 2003; 349(20): 1893-1906.doi: 10.1056/NEJMoa032292.
  21. Velazquez E.J., Morrow D.A., DeVore A.D., Duffy C.I., Ambrosy A.P., McCague K., Rocha R., Braunwald E. PIONEER-E1F Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N. Engl. J. Med. 2019; 380(6): 539-548. doi: 10.1056/NEJMoal812851.
  22. Yusuf S., Pitt B., Davis C.E., Hood W.B., Cohn J.N. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N. Engl. J. Med. 1991; 325 (5):293-302. doi: 10.1056/NEJM199108013250501.
  23. Me Murray J.J., Packer М., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014; 371:993-1004.
  24. Kaluzna-Oleksy M., Kolasa J., Migaj J., Pawlak A., Lelonek M., Nessler J., Straburzynska-Migaj E. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class -angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kardiol. Pol. 2018; 76:381-387. D01:10.1002/ejhf.l498.
  25. Pogge E.K., Davis L.E. Evaluating the safety and tolerability of sacubitril/valsartan for HFrEF managed within a pharmacist clinic. Am J. Cardiovasc. Drugs. 2018; 18:143-151.doi: 10.1007/s40256-018-0264-5.
  26. Wachter R., Viriato D., Klebs S., Grunow S.S., Schindler М., Engelhard J., Proenca C.C., Calado F., Schlienger R., Dworak M., Balas B., Wirta S.B. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgrad Med. 2018; 130:308-316. D01:10.1080/00325481.2018.1442090.
  27. Haddad H., Bergeron S., Ignaszewski A., Searles G., Rochdi D., Dhage P., Bastien N. Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study. CJC Open. 2020; 2(5): 344-353. D01:10.1016/j.cjco.2020.04.007.
  28. Solomon S.D., Rizkala A.R., Gong J., Wang W., Anand I.S., Ge J., Lam C.S.P., Maggioni A.P, Martinez F., Packer М., Pfeffer M.A., Pieske B., Redfield M.M., Rouleau J.L., Van Veldhuisen D.J., Zannad F., Zile M.R., Desai A.S., Shi V.C., Lefkowitz M.P., McMurray J.J.V. Angiotensin Receptor Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail. 2017; 5(7):471-482. D01:10.1016/j.jchf.2017.04.013.
  29. Vaduganathan M, Jhund P.S., Claggett B.L., Packer M, Widimsky J., Seferovic P., Rizkala A., Lefkowitz M, Shi V., McMurray J.J.V, Solomon S.D. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur. Eleart J. 2020; 41(25):2356-2362. D01:10.1093/eurheartj/ehaal84.
  30. Robles N.R., Campillejo R.D., Valladares J., de Vinuesa E.G., Villa J., Gervasini G. Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome. Cardiovasc. Elematol. Agents Med. Chem. 2020 May 5. doi: 10.2174/1871525718666200506095537.
  31. Lee S., Oh J., Kim H., Ha J., Chun K.H., Lee C.J., Park S., Lee S.H., Kang S.M. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020; 7(3): 1125-1129. doi: 10.1002/ehf2.12659.
  32. Seferovic J.P., Claggett B., Seidelmann S.B., Seely E.W., Packer M, Zile M.R., Rouleau J.L., Swedberg K, Lefkowitz М., Shi V.C., Desai A.S., McMurray J.J.V., Solomon S.D. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017; 5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6.
  33. Kario K. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Curr. Cardiol. Rep. 2018; 20(1):5. doi: 10.1007/sl 1886-018-0944-4.
  34. Norberg H, Bergdahl E, Lindmark K. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors. Cardiovasc. Ther. 2019 Aug 1; 2019: 6745074. doi: 10.1155/2019/6745074.
  35. Supasyndh O., Wang J., Hafeez K, Zhang Y., Zhang J., Rakugi H. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared with Olmesartan in Elderly Asian Patients (>65 years) with Systolic Hypertension. Am J. Hypertens. 2017; 30(12): 1163-1169. doi: 10.1093/ajh/hpxl 11.
  36. Cheung D.G., Aizenberg D., Gorbunov V, Hafeez K, Chen C.W., Zhang J. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. J Clin. Hypertens. (Greenwich). 2018; 20(1): 150-158. DOI: 10.111 l/jch.13153.
  37. Haynes R., Judge P.K, Staplin N., Herrington W.G., Storey B.C., Bethel A., Bowman L., Brunskill N., Cockwell P., Hill М., Kalra P.A., McMurray J.J.V., Taal M., Wheeler D.C., Landray M.J., Baigent C. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018; 138(15): 1505-1514. doi: 10.1161/CIR-CULATIONAHA. 118.034818.
  38. Desai A.S., Me Murray J.J., Packer М., Swedberg K., Rouleau J.L., Chen F., Gong J., Rizkala A.R., Brahimi A., Claggett B., Finn P. V, Hartley L.H., Liu J., Lefkowitz М., Shi V, Zile M.R., Solomon S.D. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur. Heart. J. 2015; 36(30): 1990-1997. D01:10.1093/eurheartj/ehvl86.
  39. Gan L., Langenickel Т., Petruck J, Kode K., Rajman I., Chandra P., Zhou W., Rebello S., Sunkara G. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J. Clin. Pharmacol. 2016; 56(1): 78-86. doi: 10.1002/jcph.571.
  40. Shi V., Senni М., Streefkerk H., Modgill V., Zhou W., Kaplan A. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Int. J. Cardiol. 2018; 264:118-123. D01:10.1016/j.ijcard.2018.03.121.
  41. Государственный реестр лекарственных средств [Электронный ресурс] Режим доступа http://grls.rosmin-zdrav.ru

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies